 TRPP Cation Channels
"TRPP Cation Channels" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subgroup of TRP cation channels that are widely expressed in various cell types. Defects are associated with POLYCYSTIC KIDNEY DISEASES.
| Descriptor ID |
D050396
|
| MeSH Number(s) |
D12.776.157.530.400.150.900 D12.776.157.530.400.901.777 D12.776.543.585.400.150.900 D12.776.543.585.400.901.777
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "TRPP Cation Channels".
Below are MeSH descriptors whose meaning is more specific than "TRPP Cation Channels".
This graph shows the total number of publications written about "TRPP Cation Channels" by people in this website by year, and whether "TRPP Cation Channels" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 0 | 3 | 3 | | 2009 | 2 | 1 | 3 | | 2010 | 2 | 2 | 4 | | 2011 | 0 | 1 | 1 | | 2012 | 2 | 1 | 3 | | 2013 | 2 | 0 | 2 | | 2014 | 4 | 0 | 4 | | 2015 | 1 | 0 | 1 | | 2016 | 2 | 0 | 2 | | 2017 | 0 | 1 | 1 | | 2018 | 0 | 3 | 3 | | 2019 | 2 | 3 | 5 | | 2020 | 1 | 2 | 3 | | 2021 | 0 | 1 | 1 | | 2022 | 1 | 2 | 3 | | 2024 | 1 | 4 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "TRPP Cation Channels" by people in Profiles.
-
Sedaka R, Lovelady C, Hallit E, Duyvestyn B, Shinde S, Moran-Reyna A, Lee G, Yamaguchi S, Maynard CL, Saigusa T. Intestinal barrier function declines during polycystic kidney disease progression. Am J Physiol Renal Physiol. 2025 Feb 01; 328(2):F218-F229.
-
Atwood D, He Z, Miyazaki M, Hailu F, Klawitter J, Edelstein CL. Early treatment with 2-deoxy-d-glucose reduces proliferative proteins in the kidney and slows cyst growth in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease (PKD). Cell Signal. 2024 Nov; 123:111351.
-
Yamaguchi S, Sedaka R, Kapadia C, Huang J, Hsu JS, Berryhill TF, Wilson L, Barnes S, Lovelady C, Oduk Y, Williams RM, Jaimes EA, Heller DA, Saigusa T. Rapamycin-encapsulated nanoparticle delivery in polycystic kidney disease mice. Sci Rep. 2024 07 02; 14(1):15140.
-
Chaudhary A, He Z, Atwood DJ, Miyazaki M, Oto OA, Davidoff A, Edelstein CL. Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models. Am J Physiol Renal Physiol. 2024 Jun 01; 326(6):F1004-F1015.
-
Fedeles BI, Bhardwaj R, Ishikawa Y, Khumsubdee S, Krappitz M, Gubina N, Volpe I, Andrade DC, Westergerling P, Staudner T, Campolo J, Liu SS, Dong K, Cai Y, Rehman M, Gallagher AR, Ruchirawat S, Croy RG, Essigmann JM, Fedeles SV, Somlo S. A synthetic agent ameliorates polycystic kidney disease by promoting apoptosis of cystic cells through increased oxidative stress. Proc Natl Acad Sci U S A. 2024 Jan 23; 121(4):e2317344121.
-
Krappitz M, Bhardwaj R, Dong K, Staudner T, Yilmaz DE, Pioppini C, Westergerling P, Ruemmele D, Hollmann T, Nguyen TA, Cai Y, Gallagher AR, Somlo S, Fedeles S. XBP1 Activation Reduces Severity of Polycystic Kidney Disease due to a Nontruncating Polycystin-1 Mutation in Mice. J Am Soc Nephrol. 2023 01 01; 34(1):110-121.
-
Oto OA, Edelstein CL. The Pathophysiology of Left Ventricular Hypertrophy, beyond Hypertension, in Autosomal Dominant Polycystic Kidney Disease. Nephron. 2024; 148(4):215-223.
-
Hopp K, Kleczko EK, Gitomer BY, Chonchol M, Klawitter J, Christians U, Klawitter J. Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease. Am J Physiol Renal Physiol. 2022 03 01; 322(3):F258-F267.
-
Arroyo J, Escobar-Zarate D, Wells HH, Constans MM, Thao K, Smith JM, Sieben CJ, Martell MR, Kline TL, Irazabal MV, Torres VE, Hopp K, Harris PC. The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1RC/RC mouse model of autosomal dominant polycystic kidney disease. Kidney Int. 2021 06; 99(6):1392-1407.
-
Vien TN, Ng LCT, Smith JM, Dong K, Krappitz M, Gainullin VG, Fedeles S, Harris PC, Somlo S, DeCaen PG. Disrupting polycystin-2 EF hand Ca2+ affinity does not alter channel function or contribute to polycystic kidney disease. J Cell Sci. 2020 12 24; 133(24).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|